Merck Aims for $70B Revenue by Mid-2030s on Keytruda+INBRX-106 Strength

Merck & Co., Inc. (NYSE:MRK) has set its sights on reaching $70B in human health revenue by the mid-2030s.

This ambitious goal is driven by a portfolio shift, new launches, and clinical data, with Keytruda plus INBRX-106 being a key driver of growth.

The combination treatment showed impressive results, with a confirmed objective response rate of 48.3% compared to 26.5% for Keytruda alone, as well as a median progression-free survival (PFS) of 9.6 months versus 4.9 months for the individual treatments.